Who Paid My Doc
Sara Qureshi
Neurology Billings, MT Medical Doctor
NPI 1821309071 CMS profile 1319218
801 N 29Th St, Billings, MT 59101
General payments
$12,015
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$1,327,322
Through program year 2025, Sara Qureshi of Billings, MT is reported in the CMS Open Payments database as having received $12,015 across 33 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,327,322 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 77th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $507 | 5 | |
| 2024 | General | $14 | 1 | |
| 2022 | General | $73 | 1 | |
| 2021 | General | $72 | 3 | |
| 2019 | General | $11,349 | 23 |
Beside peers
- Sara Qureshi
- Neurology median
- Middle half of Neurology
- National median
In program year 2025, general payments to Sara Qureshi were reported at $507. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.
Show as a table
| Year | Sara Qureshi | Neurology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $11,349 | $474 | $118–$2,177 | $163 |
| 2020 | $0 | $367 | $82–$2,309 | $114 |
| 2021 | $72 | $438 | $104–$2,547 | $132 |
| 2022 | $73 | $442 | $103–$2,388 | $149 |
| 2023 | $0 | $464 | $119–$2,312 | $160 |
| 2024 | $14 | $468 | $119–$2,323 | $164 |
| 2025 | $507 | $457 | $118–$2,344 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 36 drugsPart D claims
1,458
Drug cost
$2,903,767
Branded share of claims
46.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Kesimpta Pen Ofatumumab | Brand | 100 | $892,894 | |
| Copaxone Glatiramer Acetate | Brand | 130 | $767,325 | |
| Avonex Pen (4 Pack) Interferon Beta-1a | Brand | 28 | $250,591 | |
| Aubagio Teriflunomide | Brand | 21 | $249,976 | |
| Vumerity Diroximel Fumarate | Brand | 20 | $166,161 | |
| Plegridy Pen Peginterferon Beta-1a | Brand | 14 | $115,589 | |
| Gilenya Fingolimod Hcl | Brand | 11 | $103,427 | |
| Ampyra Dalfampridine | Brand | 22 | $93,095 | |
| Teriflunomide | Generic | 94 | $82,529 | |
| Glatopa Glatiramer Acetate | Brand | 28 | $59,034 |
The 10 drugs with the highest cost, of 36 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$27,422
Medicare patients
173
Services billed
480
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 56% | |
| Arthritis | 46% | |
| Depression | 40% | |
| Osteoporosis | 19% | |
| Diabetes | 15% | |
| Chronic kidney disease | 12% | |
| Cancer | 12% | |
| Ischemic heart disease | 11% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ZEPOSIA |
|
$14 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
33 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurology in Montana
Related records
Neurology in Montana
Practitioners in the same specialty and state, ranked by reported value.
All Neurology
Everyone recorded under this specialty, nationwide.
Doctors in Montana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.